Costs From ICER’s Unsupported Price Increase List Tick Back Up

The Institute for Clinical and Economic Review’s report on unsupported price increases found that combined, the 10 drugs that had net price increases that contributed the most to US health care system spending from 2021 to 2022 added an estimated $1.27bn in additional costs. That total is substantially higher than the $805m in added costs ICER estimated from its last survey, published in December 2022, but still exponentially lower from the findings of its initial unsupported price increase list in 2019 that found $4.8bn in additional costs for the US health care system.